Información del producto
- (1R,3aS,3bR,5aS,15aS,15bS,17aS)-1-Ethynyl-2,3,3a,3b,4,5,5a,6,15,15a,15b,16,17,17a-tetradecahydro-15a,17a-dimethyl-1H-benzimidazo[2,1-b]cyclopenta[5,6]naphtho[1,2-g]quinazolin-1-ol
- 1H-Benzimidazo[2,1-b]cyclopenta[5,6]naphtho[1,2-g]quinazolin-1-ol, 1-ethynyl-2,3,3a,3b,4,5,5a,6,15,15a,15b,16,17,17a-tetradecahydro-15a,17a-dimethyl-, (1R,3aS,3bR,5aS,15aS,15bS,17aS)-
- 1H-Benzimidazo[2,1-b]cyclopenta[5,6]naphtho[1,2-g]quinazolin-1-ol, 1-ethynyl-2,3,3a,3b,4,5,5a,6,15,15a,15b,16,17,17a-tetradecahydro-15a,17a-dimethyl-, [1R-(1α,3aβ,3bα,5aβ,15aα,15bβ,17aα)]-
- WIN 51708 hydrate
- Win 51708
Win 51708 is a dopamine agonist that binds to the D1 and D2 receptors in the rat striatal region. The drug has dose-dependent effects, with low doses inducing a decrease of acetylcholine release, while high doses induce an increase in acetylcholine release. Win 51708 also interacts with the antinociceptive properties of camp and inhibits bladder contractions induced by neurokinin-1 receptor activation.
Propiedades químicas
Consulta técnica sobre: 3D-UFA17730 Win 51708 hydrate
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.